BIC/FTC/TAF Efficacy and Safety Similar to DTG-Based 3-Drug Regimens at Wk 144 in ART-Naive Patients Aged 50 Yrs or Older

Slides from Dr John Baxter and Clinical Care Options (CCO): Transmitted drug resistance does not necessarily preclude the use of many first line ART options.

John D. Baxter, MD Released: January 24, 2022

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for older patients with renal impairment or liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: January 13, 2022

Free slides from CCO featuring data on racial inequities in HIV care in BIPOC communities and strategies to combat racial disparities in HIV

Solange L. Baptiste, ScM Rageshri Dhairyawan, MBBS, BSc, FCRP, DipGUM, DipHIV, DFSRH Samantha V. Hill, MD, MPH David Malebranche, MD, MPH Released: January 11, 2022